Symbiosis can integrate lyophilisation (freeze drying) or gas overlay to liquid fill options as part of aseptic filling processes within our GMP facility.
Lyophilisation is often favoured as a manufacturing step across biopharmaceuticals and small molecule drugs alike due to its contribution to product stability and handling. However, integrating a lyophilisation step should not be a last-minute decision, as development timelines can take several months.
Symbiosis has extensive experience in offering lyophilisation services as part of aseptic filling for small molecules and biopharmaceuticals such as mAbs.
Whether the lyophilisation cycle has been fully developed and is ready to be transferred or our expert team needs to assist with the development or optimisation of the cycle, we are experienced in handling a range of technical lyophilisation challenges directly, or in partnership with our trusted network.
We have two fully independent Tofflon lyophilisers contained within individual GMP manufacturing suites offering the following capabilities:
We have extensive experience in taking precious, complex drug products from manufacture to QP release.
Clinical and small scale commercial manufacturing of advanced therapeutics such as viral vectors for cell and gene therapies, oncolytic viruses and critical raw materials such as plasmids.
Extensive experience in delivering hundreds of projects allowing us to support your clinical trials.
Symbiosis can support with challenging manufacturing and handling requirements that need specialist knowledge and experience.
Overcome your development and manufacturing challenges with a partner that has the experience and capabilities to handle your highly potent ADC
Symbiosis has provided GMP manufacturing across a wide range of small molecule applications, including highly potent materials requiring specialist handling.